Ryvu Therapeutics independently discovers and develops new drug candidates. This allows the company to control the entire research process—from understanding the disease mechanism and selecting the therapeutic target to evaluating the safety and efficacy of the developed compound.
One of the company’s most advanced projects is romaciclib, previously known as RVU120. It is a selective inhibitor of CDK8 and CDK19 kinases, which participate in regulating processes essential for the survival and proliferation of cancer cells. The compound is being studied as a potential therapy for acute myeloid leukemia, myelofibrosis, and other cancers, among others.
The company also develops the ONCO Prime platform, which uses cellular models, patient-derived material, screening studies, and biological data analysis to identify new targets for precision medicine.
Ryvu conducts its own clinical and preclinical programs while collaborating with international companies and organizations from the biotechnology and pharmaceutical sectors. Through the combination of its own research infrastructure, scientific team, and international partnerships, the company participates in developing therapies that may expand treatment options for cancer patients in the future.
